Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes

  • Kamlesh Khunti ,

    Affiliation Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom

  • Hamidreza Mani,

    Affiliation Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom

  • Felix Achana,

    Affiliations Department of Health Sciences, University of Leicester, University Road, Leicester United Kingdom, Clinical Trials Unit, Medical School, University of Warwick, Coventry, United Kingdom

  • Nicola Cooper,

    Affiliation Department of Health Sciences, University of Leicester, University Road, Leicester United Kingdom

  • Laura J. Gray,

    Affiliation Department of Health Sciences, University of Leicester, University Road, Leicester United Kingdom

  • Melanie J. Davies

    Affiliation Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom

Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes

  • Kamlesh Khunti, 
  • Hamidreza Mani, 
  • Felix Achana, 
  • Nicola Cooper, 
  • Laura J. Gray, 
  • Melanie J. Davies



Screening for type 2 diabetes (T2DM) and individuals at risk of diabetes has been advocated, yet information on the response rate and diagnostic yield of different screening strategies are lacking.


Studies (from 1998 to March/2015) were identified through Medline, Embase and the Cochrane library and included if they used oral glucose tolerance test (OGTT) and WHO-1998 diagnostic criteria for screening in a community setting. Studies were one-step strategy if participants were invited directly for OGTT and two, three/four step if participants were screened at one or more levels prior to invitation to OGTT. The response rate and diagnostic yield were pooled using Bayesian random-effect meta-analyses.


47 studies (422754 participants); 29 one-step, 11 two-step and seven three/four-step were identified. Pooled response rate (95% Credible Interval) for invitation to OGTT was 65.5% (53.7, 75.6), 63.1% (44.0, 76.8), and 85.4% (76.4, 93.3) in one, two and three/four-step studies respectively. T2DM yield was 6.6% (5.3, 7.8), 13.1% (4.3, 30.9) and 27.9% (8.6, 66.3) for one, two and three/four-step strategies respectively. The number needed to invite to the OGTT to detect one case of T2DM was 15, 7.6 and 3.6 in one, two, and three/four-step strategies. In two step strategies, there was no difference between the response or yield rates whether the first step was blood test or risk-score. There was evidence of substantial heterogeneity in rates across study populations but this was not explained by the method of invitation, study location (rural versus urban) and developmental index of the country in which the study was performed.


Irrespective of the invitation method, developmental status of the countries and or rural/urban location, using a multi-step strategy increases the initial response rate to the invitation to screening for diabetes and reduces the number needed to have the final diagnostic test (OGTT in this study) for a definite diagnosis.


Type 2 diabetes (T2DM) affects over 316 million people worldwide and is expected to rise to 552 million by 2030. [1] It is associated with high morbidity, mortality and healthcare costs. [2] Screening for diabetes is feasible and identifies people with modifiable cardiovascular risk. [3] Increasing global prevalence of people at high risk of diabetes [4] supports a case for early detection and initiation of treatment of T2DM to prevent a high incidence of mortality and morbidity. Screening for both diabetes and those at high risk followed by lifestyle interventions has been suggested as being cost-effective [5,6] and may reduce long term complications. [6,7] T2DM certainly meets many of the screening criteria. [8] There is evidence that screening for diabetes has an overall benefit [6] with no harm to patients. [9] Many international organisations [2,6,7,10] have produced guidelines on screening for T2DM with information on screening tests and populations, yet none have made major recommendations regarding the strategies to approach screening and the method of invitation.

There are a number of tests available for screening and diagnosing people with T2DM and those at high risk of diabetes. One of the widely used methods is the oral glucose tolerance test (OGTT).[4] However, other methods have also been suggested such as fasting plasma glucose, [7] and non-invasive risk scores such as the FINDRISC. [11] Recently glycated haemoglobin (HbA1c) has been suggested as a diagnostic tool by WHO [4] but it is still not universally standardized and many countries still recommend using OGTT. [4] NICE Guidance suggests the use of various non-invasive screening tools followed by the use of diagnostic blood tests for identifying those with diabetes or at high risk[6]. Cost, pragmatic problems in installation of a new test, and higher prevalence of conditions such as haemoglobinopathies which undermine the accuracy of HbA1c results are barriers to use this test in some developing countries.[1215] A number of studies have reported various combinations of methods of screening including the use of risk scores which help in targeted screening followed by an OGTT. [16,17] These risk score assessments are either patient led [11] or computer generated from general practice records. [18,19]

However, there has been some uncertainty about the uptake of diabetes screening programmes in the real world setting. [20] Evidence on response to medical screening invitations has varied depending on a number of factors including the level of social deprivation[21], information on the severity of the disease, possible benefits of screening [22], the information provided [23], and levels of anxiety. [24,25] Questions still remain about how screening should be performed, in terms of producing the highest response rate and diagnostic yield.

Our objective was to perform a systematic review and meta-analysis of responses to different methods of screening and their diagnostic yield using OGTT as an example of a definite diagnostic test. We also sought to assess the effect of the countries developmental status, invitation type, locality and whether an invasive or non-invasive initial test was included on these outcomes.


A systematic review was conducted to identify published articles on screening for T2DM. We searched Medline, Embase and Cochrane online databases (1998- March/2015) using the headings of ‘Diabetes’, ‘Pre*diabet*’, “Glycemia’, ‘Impaired glucose tolerance’, ‘Impaired fasting’, ‘Screening’, etc. (Search strategies are included in the S1 Search Strategies). The reference lists of all publications included at the full text review were checked manually. Only English language papers were included.

Study selection

The initial search was performed by one reviewer and updated by another. A second reviewer reviewed all the abstracts in the first search and 30% random selection of the updated searches. All the selected full text articles were reviewed by two people. If any disagreement was not solved through discussion a third reviewer was involved. Studies were included if the subjects were free from T2DM at baseline, over the age of 18 and the screening and recruitment was population based in a community setting and the WHO 1998/9 criteria [26] was used for diagnosis and the outcome of the study included diagnostic yield.

Quality Assessment and Data extraction.

We used established guidelines on reporting observational studies [27,28] to develop our quality assessment tool (Text and Table A in S1 Quality Assessment). Each reviewer scored the selected papers separately. Inter-reviewer agreement achieved in 90%.

Authors (n = 15) were contacted via e-mail for missing data and followed up after 2–3 weeks and unfortunately only five responded. Information on the study design, invitation method, risk stratification, screening steps, age, geographical location, locality of settlement (urban versus rural), were extracted. Prevalence of the diagnosis of T2DM, and those at high risk of diabetes were extracted directly and the response rate to each test was calculated using data available in the article. High risk population were defined as those with impaired glucose regulation: either impaired fasting glucose [6·1 mmol/l (110 mg/dl) ≤ fasting glucose < 7 mmol/l (140mg/dl)] or impaired glucose tolerance [7·8 mmol/l (140 mg/dl) ≤ 2 hours OGTT blood glucose < 11·1 mmol/l (200 mg/dl)] or both.

Statistical methods

Outcome measures.

We classified the screening strategies into one of three categories based on the number of screening steps or stages employed by individual studies. Studies were classified as a) one-step if participants were invited directly for OGTT without undergoing any pre-screening step, b) two-step if participants were invited for OGTT only after undergoing one intermediate screening assessment to identify those at high risk of diabetes and c) three/four-step if participants were invited for OGTT after undergoing pre-OGTT screening assessments at two or three intermediate stages. The type of test employed at the intermediate steps included administering non-invasive tools such as risk questionnaires or computer risk-scores or invasive techniques (blood test) such as fasting or random glucose to identify at risk individuals.

For each strategy outlined above, we considered four outcomes i) initial response rate; defined as the proportion of people accepted the invitation to a screening study divided by the total number invited, ii) OGTT response rate defined as number responding to OGTT screening invitation divided by the total number invited to OGTT, iii) T2DM yield rate defined as the number of newly diagnosed T2DM cases detected by OGTT divided by total number screened using OGTT and iv) Diabetes and high risk yield rate defined as the combined number of T2DM case and those at high risk of developing diabetes detected at the OGTT divided by total number screened using OGTT.

The response rates were applied to a hypothetical population with 1000 adults to compare the yield for each strategy (one step to multi-step) to demonstrate how the different approaches compare if these strategies were implemented in a community setting.

Random effects model

The number of participants responding to a screening invitation or testing positive for diabetes or at risk of diabetes was assumed to be drawn from a binomial distribution so that each study independently estimated its own probability of response and a positive test. The logit of the response and yield probabilities were assumed to be drawn from a normal distribution and pooled across studies using Bayesian random effects meta-analysis.

The number needed to screen (NNS) to detect one T2DM case or the combined endpoint of “diabetes and high risk” was calculated as the inverse of the respective mean yield rates.

The association between screening outcomes (i.e. response and yield rates) and pre-specified study-level characteristics were explored and reported as response or yield rate ratios through univariate meta-regression. To calculate these rate ratios, studies were classed according to: i) the method of screening invitation or recruitment (postal/letter versus home visit/face-to-face invitation), ii) the pre-OGTT step screening tests (invasive test versus non-invasive test), iii) the developmental index of study’s country as defined by the United Nations Development programme (developed versus developing country), and iv) the locality of the screening (urban versus rural). The required rate ratios were defined simply as the pooled response or yield rate in one category of a study-level characteristic (for example method of invitation) divided by the corresponding pooled rate in a second category of study-level characteristic which has been designated as the reference category. For example, in the meta-regression model investigating the association between screening outcomes and method invitation, the response rate ratio was calculated as the pooled response rate in the postal invitation group divided the pooled response rate in the non-postal (home visit or face-to-face) invitation group. The yield rate ratio is defined similarly as the ratio of yield in the postal group to the yield in the non-postal group. All rate ratios were estimated on the log-odds scale to ensure the assumptions underlying the random effects meta-analysis model are applicable. Note that in the meta-regression models, studies were excluded if they provided partial or insufficient information to enable the association between a particular study-level characteristic and screening outcomes to be investigated. Heterogeneity of outcomes was quantified using the between-study standard deviation in rates on the log-odds scale.

The impact of study quality on pooled OGTT response and yield rates was investigated by restricting the analysis to studies with good quality ratings in a sensitivity analysis (Table A and B in S1 Sensitivity Analysis).

All analyses were carried out using Markov Chain Monte Carlo simulations implemented in the WinBUGS software version 1·4·3. [29] Minimally informative prior distributions were placed on parameters so that the analysis results are almost entirely determined by the data (model code is presented in the S1 WinBUGS code: Random affects meta-analysis). 95% credible intervals are presented throughout.


Electronic searches and study selection

The flowchart of study identification and selection has been shown in Fig 1. The search identified 21398 articles, of which 395 were selected for full text review and 72 were included for data extraction. Eleven studies [3040] had to be excluded in this stage due to lack of data or incomplete reported data. Remaining 61 articles [41100] were from 47 studies as some authors had published their results in multiple articles and we reviewed all these related articles to increase the accuracy of extracted data.

Fig 1. PRISMA Flowchart of paper selection.

† References –30–41. ‡ This is the number of journal articles included which equals to 47 studies as some studies had reported their results in more than one paper.

Characteristic of included studies

Tables 1 and 2 present summary statistics of the remaining 47 studies included in the analysis grouped by the type of screening strategy. Twenty-three (49%) of the included studies were conducted in Europe, 16 studies (34%) in Asia, 4 (8·5%) in Australia and New Zealand, 2 (4.3%) in the United States of American and another 2 (4.3%) in Africa. The age of participants ranged from 18 to 94 years and about half of the studies were of mixed urban rural location.

Table 1. Characteristics of studies conducting a one- step screening strategy using only OGTT.

Table 2. Characteristics of studies conducting multi—step screening strategies.

Some studies were excluded from respective outcome analyses as they provided incomplete information on response to OGTT, [4147] initial response, [41,42,4450] and yield for high risk group. [4150] Overall, 42 studies were included in the OGTT response rate, 38 in the initial response rate, and 35 in the combined “T2DM and at risk of diabetes” yield analysis.

Twenty-nine (61·7%) used OGTT alone (one-step screening approach (Table 1), 11 (23·4%) used the two-steps screening strategy, three (6·6%) used a three-step strategy and four (8·8%) used a four-step strategy. The intermediate strategies in these multi-step approaches included risk score, fasting or random glucose and HbA1c.

Response rates

Estimates of pooled screening response rates are presented in Fig 2. The response rate for OGTT as a proportion of those invited for OGTT was similar in studies using one-step and two-step strategies at approximately 65% and higher in studies using a three/four-step strategy at 85·4%. Among the studies using a multi-step screening strategy, the response rate to the initial screening invitation was 79·5% for the two-step strategy which is higher than the estimated 55·4% response the rate for studies using three/four-step strategy but there was considerable overlap in the uncertainty (i.e. 95% credible intervals) around these estimates (Fig 1). Only the studies using a three/four-step strategy had an intermediate screening step which had a pooled response rate of 69·7%.

Fig 2. Pooled response rates to diabetes screening invitation.

Estimates are from Bayesian random effects meta-analysis. CrI = Credible intervals which is similar to a confidence intervals generated using Frequentist statistics.

Positive outcome at initial and intermediate screening stages

The proportion of individuals screened positive (i.e. identified as being at risk of T2DM) at the initial and intermediate stages of the multi-step strategies are summarised in Fig 3. These are the individuals who needed to have the next step of the screening study. The positive outcome rate was similar for two-step and three/four-step at 31.1% and 37.4% respectively at the initial step and remained relatively the same for the intermediate screening step.

Fig 3. Pooled positive outcome rates of diabetes screening using risk score, risk questionnaire and impaired glucose test.

Estimates are from Bayesian random effects meta-analysis. CrI = Credible intervals which is similar to confidence intervals generated using Frequentist statistics.

Yield rates

Pooled estimates of the yield for T2DM and the high risk (combined endpoint of T2DM and those at high risk of diabetes) are presented in Fig 4. Yield for OGTT T2DM increased from 6·5% (5·3, 7·8) in the one-step to 13·1% (4·3, 30·9) in the two-step and 27·9% (8·6, 66·3) in the three/four-step strategy. These yield rates correspond to number needed to screen with OGTT to detect one case of diabetes of about 15, 7.6 and about 3·5 persons respectively.

Fig 4. Pooled yield rates from diabetes screening meta-analysis.

Estimates are from Bayesian random effects meta-analysis. CrI = Credible intervals which is similar to a confidence intervals generated using Frequentist statistics. NNS* = Number needed to screen at OGTT step to detect one case of type 2 diabetes. NNS** = Number needed to screen at initial screening step (if a multi-step strategy is used) to detect to detect one case of type 2 diabetes.

The overall T2DM yield (i.e. the total number of diabetes cases detected at all the steps as a proportion of those screened at the initial step) in the multi-step strategy studies decreased from the 6·5% in the one-step strategy reported above to 3.6% (2·6, 4.9) in the two-step strategy and 3·2% (95% CrI 2·0, to 5·1) in the three/four-step strategy. These rates corresponds to an increase in the number needed to screen at the initial step (OGTT if one-step strategy) from 15 in a one-step strategy to 28 and 31 in two-step and three/four-step strategies respectively.

Pooled estimates of the yield for the high risk (the combined endpoint of T2DM and those at high risk of diabetes) were 25·8% (22·3, 29·5), 27.7% (13·3, 49·0) and 75·3% (43·5, 92·4) for studies adopting one, two or three/four-step strategies respectively. The number needed to screen to detect one additional person with diabetes or at risk of diabetes was decreased from 4 in a one-step strategy to 3·5 and 1 in two-step and three/four-step strategies.

We applied the mean response and yield rates from the meta-analysis to a hypothetical population of 1000 individuals in order to determine the diagnostic yield of the three screening strategies (Fig 5). The number of individuals screened using OGTT decreased from 650 in a one-step strategy to 156 and 45 in two-step and three/four-step screening strategies respectively, and the number of T2DM cases identified decreased from 42 cases in one-step strategy to 28 and 18 in the two-step and three/four-step strategies respectively.

Fig 5. Modelling the screening outcome in a community with 1000 adult population.

*One Step strategy = Direct invitation to OGTT (Studies in Table 1). **Two- Step strategy = One step screen before OGTT (Studies in Table 2). ***Three/Four Step Studies = Two or three screening steps before OGTT (Studies in Table 2).

Invasive versus Non-invasive tests

Seven of the 11 studies with a two-step strategy used an invasive test at the first screening step (Table 2). There was no evidence that the OGTT response rate was higher in studies using an invasive test than those using a non-invasive test [response rate ratio = 1·5, (0·3, 5·7)]. There was a non-significant increase in the yield for T2DM and combined end point of the T2DM and high risk population in studies using invasive test compared to non-invasive methods [yield rate ratio were 6·4 (0·8, 43·9) and 2·3 (0·4, 13·3) respectively]. To compare the initial response rates one study had to be excluded [19] as a computerised risk score was applied instead of sending participants a risk questionnaire. Among the nine studies, there was no evidence to suggest that the initial screening response differed between invasive and non-invasive screening tests [response rate ratio = 4·9 (0·6, 43·7)].

The effect of invasive versus non-invasive tests on the outcomes of the three/four-step strategies was not investigated as 6 of 7 studies employing this strategy used both invasive and non-invasive tests at the intermediate screening steps.

Other covariate effect and subgroup analyses

Association between screening outcomes and three study-level characteristics: developed versus developing country, invitation method, and urban-rural level are presented in Table 3. There was no evidence that screening and yield rates were associated with a country’s developmental index, the invitation method and the rural or urban location of the community.

Table 3. Association between screening outcomes and study level characteristics:- i) developed/developing country ii) rural/urban location and iii) invitation method and screening response and yield rates from random effects meta-analysis of T2DM screening studies.


The estimates of the between-study standard deviation (τ on the log-odds scale presented in S1 Sensitivity Analysis) indicate a high degree of heterogeneity in rates across studies using a one-step, two-step and three/four-step strategies.

Sensitivity analysis

Restricting the analysis to studies assessed as good quality (S1 Quality Assessment) did not substantially alter pooled OGTT response and yield rates. The effect of study quality was not investigated for the initial and intermediate screening outcomes because of insufficient data at these steps.

In result reported above, we specified the following minimally informative prior distributions: i) Normal (0, 103) for pooled rate on the log-odds scale ii) Uniform (0,100) for the between-study standard deviation. To investigate sensitivity of our results to the choice of prior distributions, we conducted sensitivity analyses for the response and yield outcomes in which we changed the prior distributions to iii) Normal (0, 106) for the pooled rate and ii) Inverse-Gamma (0.001, 0.001) for the between-study variance. The pooled OGTT response rate was 65.2% (53.2% to 75.8%) for one-step strategy, 63.1% (48.2% to 76.9%) for a two-step strategy and 85.1% (78.8% to 91.7) for a three/four-step strategy. These are very similar to main analysis results (Fig 2) suggesting minimal impact of the prior distributions on the pooled response rates. The sensitivity analyses were repeated for the yield outcomes and meta-regression analyses (results not shown) with the same minimal effect on overall pooled rates.


We have summarised and quantified the response and diagnostic yield rates of different screening strategies for T2DM and the high risk population. Our meta-analysis indicates that, for those invited for OGTT screening, the number needed to screen to detect one T2DM case decreases as the number of screening steps increases. We also showed that while the response rates to OGTT invitation is the same for one and two steps screening strategies, the two-step screening study has higher response rate to the initial screening invitation. In the two-step strategies, there was no difference in the response and yield rates whether a blood test was used as the initial screening step or a risk-score. We also showed that the method of invitation did not impact the response rate; whether it was face to face or through post.

The use of risk classification and reclassification is based on the assumption that individuals should be stratified into clinically relevant risk categories and for most risk scores the area under the receiver operating characteristic curve generally range from 0.7 to 0.8, [101] which is seen as an acceptable level of discrimination. Therefore the absolute number of people identified with diabetes or high risk decreases as the number of steps increases (see Fig 3). However, a reduced number of OGTTs are performed to find a higher proportion of people with T2DM or those at high risk. This is both the result of screening out the low risk population and also the number of people who are not responding in each intermediary steps. Ultimately a pragmatic point is that less people need to have OGTT screening when the screening steps increase. This has been suggested to be the most cost effective method [6, 102] and our study confirms the two step methods has higher initial response rate to invitation, similar response rate to OGTT invitation and higher yield rates.

Comparison with previous studies and recommendations

Screening for a condition is justified only if there is a net benefit in early detection and treatment of the condition as compared to its natural clinical presentation. [103, 104] It has been suggested that T2DM passes this test if a lifestyle intervention is implemented to prevent diabetes in the high risk population. [5, 6] It is argued that universal screening would not be effective or worthwhile, and that populations at risk should be identified and targeted. [105, 106] The impact of screening at population and individual level, costs, type of test to use, and its effectiveness have been highlighted as important factors in decision making [104, 105]. The evidence for management of newly diagnosed diabetes and those at high risk of diabetes for early intervention [107] and prevention [5, 108111] is compelling. The ADDITION study demonstrated that when compared to routine care, an intervention to promote target-driven, intensive management of patients with type 2 diabetes detected by screening was associated with modest but significant differences in prescribed treatment and levels of cardiovascular risk factors at five years. [112]

The question to answer is the methodology to approach to the screening task. Screening a population using a non-invasive risk stratification tool followed by a definite blood test seems the most cost-effective method of screening for T2DM and those at high risk [6, 102]. Stepwise approach and adding an initial screening test (biochemical or risk score) before the “definitive test” increases the yield from OGTT. Recently National Institute for Clinical Excellence also recommended [6] screening for high risk population and offering blood test for those at high risk of diabetes. Our results confirm this and may have an impact on the cost-effectiveness of this recommendation.

Unfortunately due to lack of qualified studies we were unable to compare screening using different tests such as random or fasting blood glucose, HbA1c, or the risk score as the initial screening step. One study used HbA1c as a screening step [100]. It would also, be ideal if we could report the difference between self-scoring and applied risk score and compare their impact on the response rate to OGTT and overall yield of diabetes.

This is the first meta-analysis to determine response and yield rate when screening for T2DM and people at high risk of diabetes. We used a wide terminology in initial searching for the papers to increase the capture of the publications and reduce missing papers. There was a variety of approaches in invitation and steps prior to the final definitive test (OGTT) and this restricted the meta-analysis and subgroup analysis of the data, however we used robust statistical techniques. We only included the English language papers, but made no limitation on the population size and analysed the data for different regions.

Some studies did not clearly report method of invitation, response rate or exact numbers of participants partaking in certain screening steps. However missing data is always a problem in evidence synthesis and we managed to recover some by contacting authors and or re-calculating the outcomes. Another limitation in any evidence synthesis is the fact that all studies are not really and truly the same and combining their results may not be the real reflection of the pooled outcomes. This is reflected in the high level of heterogeneity seen across all outcomes. In our study; the number and order of the tests used before OGTT, impact of the self-score versus computer generated score, differences between different risk scores, possible impact of population dynamic and the psychosocial factors, wording of the invitation letter and its impact on the response to invitation are examples of some of the possible factors which we could not truly account for their effects on our results.

We used OGTT as the definite test for diagnosis of diabetes. Although, the new guidelines [4, 113] suggest the use of HbA1c for the diagnosis of diabetes, they do not exclude the use of OGTT. Besides, some countries will continue to use OGTT as their screening tool. [1215] A detailed modelling is necessary to compare the cost-effectiveness of this approach with multi-step screening.


We have been able to provide evidence for the overall response rate and yield of diabetes screening in the background of a variety of factors such as geographical area, invitation methods and locality of the population (urban vs. rural) which influences decision making when undertaking this task.

We can conclude that performing a multi-step approach in a population screening increases the yield and decreases the number needed to screen by OGTT and in the two- step approach it even increases the initial response rate to the invitation. In terms of absolute numbers, the highest yield of diabetes, however, is obtained in the one step studies where an OGTT is offered as a screening test to the population. The process of screening for T2DM or those at high risk of diabetes needs careful re-evaluation by local policy makers in each country especially in view of our findings.


Authors would like to thank Avni Chauhan (AC) and Harriet Fisher (HF) for their help in the systematic review and data extraction.

Authors acknowledge support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care–East Midlands (NIHR CLAHRC–EM), the Leicester Clinical Trials Unit and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. The views expressed are those of the author(s) and not necessarily those of the NHS, the named universities, NIHR or the Department of Health.

Author Contributions

Conceived and designed the experiments: KK HM FA MJD. Performed the experiments: HM FA. Analyzed the data: FA HM LJG NC. Contributed reagents/materials/analysis tools: FA HM. Wrote the paper: HM FA KK. Contacted Authors of previous papers: HM.


  1. 1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94: 311–321. pmid:22079683
  2. 2. DUK. DIABETES IN THE UK 2012 Key statistics on diabetes. April 2012.
  3. 3. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia. 2008;51: 1127–1134. pmid:18443762
  4. 4. WHO. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus available from. 2011;WHO/NMH/CHP/CPM/11.1.
  5. 5. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336: 1180–1185. pmid:18426840
  6. 6. Nice P. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. 2012.
  7. 7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1: S62–7. pmid:19118289
  8. 8. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65: 281–393. pmid:4234760
  9. 9. Skinner TC, Davies MJ, Farooqi AM, Jarvis J, Tringham JR, Khunti K. Diabetes screening anxiety and beliefs. Diabet Med. 2005;22: 1497–1502. pmid:16241913
  10. 10. WHO/IDF. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia RepoRt of a WHo/IDf ConsultatIon. 2006;(NLM classification: WK 810): ISBN 978 92 4 159493 6.
  11. 11. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26: 725–731. pmid:12610029
  12. 12. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab. 2012;97: 1067–1072. pmid:22238408
  13. 13. John WG, Mosca A, Weykamp C, Goodall I. HbA1c standardisation: history, science and politics. Clin Biochem Rev. 2007;28: 163–168. pmid:18392123
  14. 14. Gomez-Perez FJ, Aguilar-Salinas CA, Almeda-Valdes P, Cuevas-Ramos D, Lerman Garber I, Rull JA. HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article. Arch Med Res. 2010;41: 302–308. pmid:20637376
  15. 15. Echouffo-Tcheugui JB, Mayige M, Ogbera AO, Sobngwi E, Kengne AP. Screening for hyperglycemia in the developing world: Rationale, challenges and opportunities. Diabetes Res Clin Pract. 2012;98: 199–208. pmid:22975016
  16. 16. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11: iii–iv, ix-xi, 1–125.
  17. 17. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343: d7163. pmid:22123912
  18. 18. Rahman M, Simmons RK, Harding AH, Wareham NJ, Griffin SJ. A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study. Fam Pract. 2008;25: 191–196. pmid:18515811
  19. 19. Gray LJ, Khunti K, Edwardson C, Goldby S, Henson J, Morris DH, et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia. 2012;55: 3238–3244. pmid:23001376
  20. 20. Goyder E, Wild S, Fischbacher C, Carlisle J, Peters J. Evaluating the impact of a national pilot screening programme for type 2 diabetes in deprived areas of England. Fam Pract. 2008;25: 370–375. pmid:18765406
  21. 21. [Anonymous]. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Family Heart Study Group. BMJ. 1994;308: 313–320. pmid:8124121
  22. 22. Jorgensen KJ, Gotzsche PC. Content of invitations for publicly funded screening mammography. BMJ. 2006;332: 538–541. pmid:16513713
  23. 23. Marteau TM, Mann E, Prevost AT, Vasconcelos JC, Kellar I, Sanderson S, et al. Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): randomised trial. BMJ. 2010;340: c2138. pmid:20466791
  24. 24. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007;335: 486. pmid:17761995
  25. 25. Eborall H, Stone M, Aujla N, Taub N, Davies M, Khunti K. Influences on the uptake of diabetes screening: a qualitative study in primary care. Br J Gen Pract. 2012;62: e204–11. pmid:22429438
  26. 26. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Report of a WHO Consultation Part 1: Diagnosis and Classification of Diabetes Mellitus. 1999;WHO/NCD/NCS/99.2: Available:
  27. 27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61: 344–349. pmid:18313558
  28. 28. Wong WC, Cheung CS, Hart GJ. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerg Themes Epidemiol. 2008;5: 23. pmid:19014686
  29. 29. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS user manual version 1.4 January 2003. Upgraded to Version 1.4.3. Available from.
  30. 30. Al-Lawati JA, Tuomilehto J. Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. Diabetes Res Clin Pract 2007 Sep;77(3):438–444. pmid:17306410
  31. 31. Egeland GM, Cao Z, Young TK. Hypertriglyceridemic-waist phenotype and glucose intolerance among Canadian Inuit: the International Polar Year Inuit Health Survey for Adults 2007–2008. CMAJ 2011 Jun 14;183(9):E553–8. pmid:21555386
  32. 32. Goyder E, Wild S, Fischbacher C, Carlisle J, Peters J. Evaluating the impact of a national pilot screening programme for type 2 diabetes in deprived areas of England. Fam Pract 2008 Oct;25(5):370–375. pmid:18765406
  33. 33. Mensink M, Corpeleijn E, Feskens EJ, Kruijshoop M, Saris WH, de Bruin TW, et al. Study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Res Clin Pract 2003 Jul;61(1):49–58. pmid:12849923
  34. 34. Oberlinner C, Neumann SM, Ott MG, Zober A. Screening for pre-diabetes and diabetes in the workplace. Occup Med (Lond) 2008 Jan;58(1):41–45.
  35. 35. Saaristo T, Peltonen M, Lindstrom J, Saarikoski L, Sundvall J, Eriksson JG, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res 2005 May;2(2):67–72. pmid:16305061
  36. 36. Sadeghi M, Roohafza H, Shirani S, Poormoghadas M, Kelishadi R, Baghaii A, et al. Diabetes and associated cardiovascular risk factors in Iran: the Isfahan Healthy Heart Programme. Ann Acad Med Singapore 2007 Mar;36(3):175–180. pmid:17450262
  37. 37. Sundborn G, Metcalf P, Scragg R, Schaaf D, Dyall L, Gentles D, et al. Ethnic differences in the prevalence of new and known diabetes mellitus, impaired glucose tolerance, and impaired fasting glucose. Diabetes Heart and Health Survey (DHAH) 2002–2003, Auckland New Zealand. N Z Med J 2007 Jun 29;120(1257):U2607. pmid:17632597
  38. 38. Ziemer DC, Kolm P, Foster JK, Weintraub WS, Vaccarino V, Rhee MK, et al. Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2. J Gen Intern Med 2008 May;23(5):528–535. pmid:18335280
  39. 39. Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010 Jun 15;152(12):770–777. pmid:20547905
  40. 40. Azizi F, Gouya MM, Vazirian P, Dolatshahi P, Habibian S. The diabetes prevention and control programme of the Islamic Republic of Iran. East Mediterr Health J 2003 Sep-Nov;9(5–6):1122–1127.
  41. 41. Mannucci E, Ognibene A, Sposato I, Brogi M, Gallori G, Bardini G, et al. Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol. 2003;40: 181–186. pmid:14740278
  42. 42. Jia WP, Pang C, Chen L, Bao YQ, Lu JX, Lu HJ, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50: 286–292. pmid:17180353
  43. 43. Das M, Hassan Z, Faruque O, Parial R, Khalequzzaman M, Ali L. Prevalence of abnormal glycemic and lipidemic status in an urban population of Bangladesh. J bio-sci. 2011;19: 1–6.
  44. 44. Habibi Moeine S, Mirmiran P, Mehrabi Y, Azizi F. Evaluation of Different Risk Factors for Early Diagnosis of Diabetes Mellitus. IJMS. 2004;29: 21–25.
  45. 45. Franciosi M, De Berardis G, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28: 1187–1194. pmid:15855587
  46. 46. Zhou X, Ji L, Luo Y, Han X, Zhang X, Sun X, et al. Risk factors associated with the presence of diabetes in Chinese communities in Beijing. Diabetes Res Clin Pract. 2009;86: 233–238. pmid:19836096
  47. 47. Zhou XH, Ji LN, Luo YY, Zhang XY, Han XY, Qiao Q. Performance of HbA(1c) for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing. Diabet Med. 2009;26: 1262–1268. pmid:20002479
  48. 48. Rush E, Crook N, Simmons D. Point-of-care testing as a tool for screening for diabetes and pre-diabetes. Diabet Med. 2008;25: 1070–1075. pmid:19183312
  49. 49. El Bassuoni EA, Ziemer DC, Kolm P, Rhee MK, Vaccarino V, Tsui CW, et al. The "metabolic syndrome" is less useful than random plasma glucose to screen for glucose intolerance. Prim Care Diabetes. 2008;2: 147–153. pmid:18779039
  50. 50. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care. 2001;24: 1377–1383. pmid:11473073
  51. 51. Amoah AG, Owusu SK, Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. Diabetes Res Clin Pract. 2002;56: 197–205. pmid:11947967
  52. 52. Botas P, Delgado E, Castano G, Diaz de Grenu C, Prieto J, Diaz-Cadorniga FJ. Comparison of the diagnostic criteria for diabetes mellitus, WHO-1985, ADA-1997 and WHO-1999 in the adult population of Asturias (Spain). Diabet Med. 2003;20: 904–908. pmid:14632715
  53. 53. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46: 182–189. pmid:12627316
  54. 54. Colagiuri S, Hussain Z, Zimmet P, Cameron A, Shaw J, AusDiab. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care. 2004;27: 367–371. pmid:14747215
  55. 55. Glumer C, Jorgensen T, Borch-Johnsen K. Targeted screening for undiagnosed diabetes reduces the number of diagnostic tests. Inter99(8). Diabet Med. 2004;21: 874–880. pmid:15270791
  56. 56. Glumer C, Jorgensen T, Borch-Johnsen K, Inter99 study. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care. 2003;26: 2335–2340. pmid:12882858
  57. 57. Simmons D, McKenzie A, Eaton S, Shaw J, Zimmet P. Prevalence of diabetes in rural Victoria. Diabetes Res Clin Pract. 2005;70: 287–290. pmid:15946759
  58. 58. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care. 2006;29: 363–367. pmid:16443888
  59. 59. Heldgaard PE, Griffin SJ. Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome. Diabet Med. 2006;23: 996–1002. pmid:16922706
  60. 60. Heldgaard PE, Henriksen JE, Sidelmann JJ, Olivarius Nde F, Siersma VD, Gram JB. Similar cardiovascular risk factor profile in screen-detected and known type 2 diabetic subjects. Scand J Prim Health Care. 2011;29: 85–91. pmid:21438763
  61. 61. Menon VU, Kumar KV, Gilchrist A, Sugathan TN, Sundaram KR, Nair V, et al. Prevalence of known and undetected diabetes and associated risk factors in central Kerala—ADEPS. Diabetes Res Clin Pract. 2006;74: 289–294. pmid:16730847
  62. 62. Mohan V, Deepa M, Deepa R, Shanthirani CS, Farooq S, Ganesan A, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India—the Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia. 2006;49: 1175–1178. pmid:16570158
  63. 63. Mohan V, Sandeep S, Deepa M, Gokulakrishnan K, Datta M, Deepa R. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians—the Chennai Urban Rural Epidemiology Study (CURES-38). Diabetes Obes Metab. 2007;9: 337–343. pmid:17391160
  64. 64. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev. 2007;23: 127–134. pmid:16752431
  65. 65. Barakat MN, Youssef RM. Prevalence of dysglycemia and other cardiovascular risk factors among the rural population of Oman. Saudi Med J. 2008;29: 1824–1826. pmid:19082242
  66. 66. Karjalainen J, Peltonen M, Vanhala M, Korpi-Hyovalti E, Puolijoki H, Saltevo J, et al. Leisure time physical activity in individuals with screen-detected type 2 diabetes compared to those with known type 2 diabetes. Diabetes Res Clin Pract. 2008;81: 110–1166. pmid:18433914
  67. 67. Bener A, Zirie M, Janahi IM, Al-Hamaq AO, Musallam M, Wareham NJ. Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar. Diabetes Res Clin Pract. 2009;84: 99–106 pmid:19261345
  68. 68. Dunkley AJ, Taub NA, Davies MJ, Stone MA, Khunti K. Is having a family history of type 2 diabetes or cardiovascular disease a predictive factor for metabolic syndrome? Prim Care Diabetes. 2009;3: 49–56. pmid:19268647
  69. 69. Gardete-Correia L, Boavida JM, Raposo JF, Mesquita AC, Fona C, Carvalho R, et al. First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med. 2010;27: 879–881. pmid:20653744
  70. 70. Cho NH, Jang HC, Choi SH, Kim HR, Lee HK, Chan JC, et al. Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. Diabetes Care. 2007;30: 2566–2568. pmid:17626893
  71. 71. Choi SH, Kim TH, Lim S, Park KS, Jang HC, Cho NH. Hemoglobin A1c as a Diagnostic Tool for Diabetes Screening and New-Onset Diabetes Prediction. Diabetes care. 2011;34: 944–949. pmid:21335372
  72. 72. Choi SJ, Keam B, Park SH, Park HY. Appropriate waist circumference cut-offs to predict diabetes in the Korean population—the Korean Genome and Epidemiology Study-. Circ J. 2010;74: 1357–1363. pmid:20519877
  73. 73. Lim S, Jang HC, Lee HK, Kimm KC, Park C, Cho NH. A rural-urban comparison of the characteristcs of the metabolic syndrome by gender in korea: The Korean Health and Genome Study (KHGS). J Endocrinol Invest. 2006;29: 313–319. pmid:16699297
  74. 74. Webb DR, Gray LJ, Khunti K, Srinivasan B, Taub N, Campbell S, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia. 2011;54: 2237–2246. pmid:21638133
  75. 75. Bhansali A, Walia R, Ravi Kumar P, Ravi Kiran M, Shanmugasundar G. Accuracy of glycated haemoglobin in screening for pre-diabetes in Asian Indians—a community survey: the Chandigarh Urban Diabetes Study (CUDS). Diabet Med. 2012;29: 1385–1389. pmid:22414322
  76. 76. Hayes L, Hawthorne G, Unwin N. Undiagnosed diabetes in the over-60s: performance of the Association of Public Health Observatories (APHO) Diabetes Prevalence Model in a general practice. Diabet Med. 2012;29: 115–120. pmid:21781154
  77. 77. Ye Z, Cong L, Ding G, Yu M, Zhang X, Hu R, et al. (2014) Optimal Cut-Off Points for Two-Step Strategy in Screening of Undiagnosed Diabetes: A Population- Based Study in China. PLoS ONE 9(3): e87690. pmid:24609110
  78. 78. Dong Y, Gao W, Nan H, Yu H, Li F, Duan W, et al. Prevalence of Type 2 diabetes in urban and rural Chinese populations in Qingdao, China. Diabet Med. 2005;22: 1427–1433. pmid:16176207
  79. 79. Eriksson AK, Ekbom A, Hilding A, Ostenson CG. The influence of non-response in a population-based cohort study on type 2 diabetes evaluated by the Swedish Prescribed Drug Register. Eur J Epidemiol. 2012;27: 153–162. pmid:22089424
  80. 80. Hilding A, Eriksson AK, Agardh EE, Grill V, Ahlbom A, Efendic S, et al. The impact of family history of diabetes and lifestyle factors on abnormal glucose regulation in middle-aged Swedish men and women. Diabetologia. 2006;49: 2589–2598. pmid:16969647
  81. 81. Korhonen PE, Jaatinen PT, Aarnio PT, Kantola IM, Saaresranta T. Waist circumference home measurement—a device to find out patients in cardiovascular risk. Eur J Public Health. 2009;19: 95–99. pmid:18927187
  82. 82. Ohkura T, Taniguchi S, Inoue K, Yamamoto N, Matsuzawa K, Fujioka Y, et al. Screening Criteria of Diabetes Mellitus and Impaired Glucose Tolerance of the Japanese Population in a Rural Area of Japan: The Tottori-Kofu Study. Yonago Acta medica. 2009;52: 105–114.
  83. 83. Rahim MA, Vaaler S, Keramat Ali SM, Khan AK, Hussain A, Nahar Q. Prevalence of type 2 diabetes in urban slums of Dhaka, Bangladesh. Bangladesh Med Res Counc Bull. 2004;30: 60–70. pmid:15813484
  84. 84. Rahim MA, Hussain A, Azad Khan AK, Sayeed MA, Keramat Ali SM, Vaaler S. Rising prevalence of type 2 diabetes in rural Bangladesh: a population based study. Diabetes Res Clin Pract. 2007;77: 300–305. pmid:17187890
  85. 85. Rahim MA, Azad Khan AK, Nahar Q, Ali SM, Hussain A. Impaired fasting glucose and impaired glucose tolerance in rural population of Bangladesh. Bangladesh Med Res Counc Bull. 2010;36: 47–51. pmid:21473200
  86. 86. Hussain A, Rahim MA, Azad Khan AK, Ali SM, Vaaler S. Type 2 diabetes in rural and urban population: diverse prevalence and associated risk factors in Bangladesh. Diabet Med. 2005;22: 931–936. pmid:15975110
  87. 87. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011;37: 144–151. pmid:21144787
  88. 88. Lin S, Hu L, Li X, Chen Y, Xu H, He S, et al. Glycated haemoglobin A c for diagnosing diabetes in Chinese subjects over 50 years old: a community-based cross-sectional study. Clin Endocrinol (Oxf). 2013.
  89. 89. Phillips LS, Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK. et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes Diabetologia (2009) 52:1798–1807 pmid:19557386
  90. 90. Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, et al. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care. 2002;25: 1784–1789. pmid:12351478
  91. 91. Sandbaek A, Lauritzen T, Borch-Johnsen K, Mai K, Christiansen JS. The comparison of venous plasma glucose and whole blood capillary glucose in diagnoses of Type 2 diabetes: a population-based screening study. Diabet Med. 2005;22: 1173–1177. pmid:16108845
  92. 92. Dalsgaard EM, Christensen JO, Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbaek A. Comparison of different stepwise screening strategies for type 2 diabetes: Finding from Danish general practice, Addition-DK. Prim Care Diabetes. 2010;4: 223–229. pmid:20675208
  93. 93. Janssen PG, Gorter KJ, Stolk RP, Akarsubasi M, Rutten GE. Three years follow-up of screen-detected diabetic and non-diabetic subjects: who is better off? The ADDITION Netherlands study. BMC Fam Pract. 2008;9: 67. pmid:19087327
  94. 94. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study. Prim Care Diabetes. 2007;1: 69–74. pmid:18632022
  95. 95. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract. 2007;24: 555–561. pmid:17962235
  96. 96. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia. 2004;47: 1566–1573. pmid:15365615
  97. 97. Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, et al. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med. 2010;27: 995–1003. pmid:20722672
  98. 98. Park P, Simmons RK, Prevost AT, Griffin SJ. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. BMC Public Health. 2008;8: 350. pmid:18840266
  99. 99. Park P, Simmons RK, Prevost AT, Griffin SJ, ADDITION Cambridge study group. A randomized evaluation of loss and gain frames in an invitation to screening for type 2 diabetes: effects on attendance, anxiety and self-rated health. J Health Psychol. 2010;15: 196–204. pmid:20207663
  100. 100. McAullay D, Sibthorpe B, Knuiman M. Evaluation of a new diabetes screening method at the Derbarl Yerrigan Health Service. Aust N Z J Public Health. 2004;28: 43–46. pmid:15108746
  101. 101. Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011;33: 46–62. pmid:21622851
  102. 102. Khunti K, Gillies CL, Taub NA, Mostafa SA, Hiles SL, Abrams KR, et al. A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: Modelling study. Diabetes Res Clin Pract. 2012;97: 505–513. pmid:22554999
  103. 103. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;138: 215–229. pmid:12558362
  104. 104. Norris SL, Kansagara D, Bougatsos C, Fu R, U.S. Preventive Services Task Force. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148: 855–868. pmid:18519931
  105. 105. WHO I. Screening for Type 2 Diabetes Report of a World Health Organization and International Diabetes Federation meeting. 2003;WHO/NMH/MNC/03.1 Available:
  106. 106. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ. 2001;322: 986–988. pmid:11312236
  107. 107. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359: 1577–1589. pmid:18784090
  108. 108. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374: 1677–1686. pmid:19878986
  109. 109. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368: 1673–1679. pmid:17098085
  110. 110. Khunti K, Davies MJ. Diabetes prevention: NICE opportunity for implementing programmes in the real-world setting. Diabet Med. 2012.
  111. 111. Khunti K, Davies M. Should we screen for type 2 diabetes: Yes. BMJ. 2012;345: e4514. pmid:22777029
  112. 112. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012.
  113. 113. John WG, on behalf of the UK Department of Health Advisory Committee on Diabetes. Use of HbA(1c) in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med. 2012;29: 1350–1357. pmid:22957983